Oncolytics Biotech Inc ONCY

Bristol Meyers Squibb CEO to step down

[Noteable]

Bristol Meyers Squibb could become another contender for ONCY because of ONCY's alignment with the Celgene immuno-oncology assets. BMS is a US$143 Billion company.

https://www.bms.com/researchers-and-partners/in-the-pipeline.html

https://endpts.com/bristol-myers-ceo-giovanni-caforio-to-step-down-in-november/

[Noteable]

Should read: Bristol Myers Squibb

[Noteable]

April 26, 2023 - Bristol Myers Squibb plans to take over a Novartis plant in a Chicago suburb to manufacture its CAR-T therapies. https://endpts.com/bristol-myers-snaps-up-former-novartis-manufacturing-site-in-illinois/ We already know how ONCY's pelareorep acts synergistically with CAR-T therapy to result in a curative effect when pelareorep is combined with CAR-T and then when

[Noteable]

"The unexpected transition means that Boerner will be responsible for guiding BMS through one of the steepest patent cliffs in the biopharma industry." https://www.fiercepharma.com/pharma/bristol-myers-caforio-hand-ceo-baton-commercial-chief-boerner "BMS joins a growing list of drugmakers that have changed their helmsmen recently. Roche, Bayer, Biogen, Seagen, Astellas, Teva and

[Noteable]

April 27, 2023 - Striking deals remains Bristol’s “top priority,” CFO David Elkins said during [Thursday's investor's call]. BMS will continue to look for deals in fields where the company has deep R&D and commercial expertise, regardless of the stage of the program, he said. Bristol’s core focus areas are solid tumors, hematology, immunology and cardiovascular disease. https